These results suggested that both miR-22 and galectin-9 inhibited HCC cell growth and metastasis in vivo and that co-transfectionwithgalectin-9 enhanced the anti-tumor effects of miR-22. Here, LGALS9 is linked to hepatocellular carcinoma.